|
⚲
|
| Keyboard |
| CR Group LP
✚
|
|
|---|---|
| CRD # | 132967 |
| SEC # | 801-63545 |
| CIK # | 0001702352, 0001747755 |
| AUM | 2,207.6 M (2026-03-31) |
| Employees | 21 (43% Investors, 0% Brokers) |
| Phone | 713-209-7350 |
| Address | 1000 Main Street, Suite 2500 Houston, TX 77002-6340 |
| Source | [IAPD] [EDGAR] [Website] [LinkedIn] |
| Total AUM ($B) |
|---|
| Type | Form D Funds | Date | Sold | AUM |
|---|---|---|---|---|
| PE | CRG Partners V Cayman Parallel Fund C LP | [2023-03-30] | 526.5 M | 371.0 M |
| Offered $2,000,000,000 · Filed 2023-09-28 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining $1,473,487,000 · Duration One year or less · Commission $77,346 · Revenue Decline to Disclose | ||||
| PE | CRG Partners V Cayman Parallel Fund LP | [2023-03-30] | 526.5 M | 77.4 M |
| Offered $2,000,000,000 · Filed 2023-09-28 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining $1,473,487,000 · Duration One year or less · Commission $77,346 · Revenue Decline to Disclose | ||||
| PE | CRG Partners V Delaware Parallel Fund LP | [2023-03-30] | 526.5 M | 95.1 M |
| Offered $2,000,000,000 · Filed 2023-09-28 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining $1,473,487,000 · Duration One year or less · Revenue Decline to Disclose | ||||
| PE | CRG Partners IV - Cayman Levered LP | [2019-03-29] | 166.1 M | |
| Filed 2019-10-11 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Revenue Decline to Disclose | ||||
| PE | CRG Partners IV LP | [2019-03-29] | 229.8 M | 165.2 M |
| Filed 2019-10-11 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Revenue Decline to Disclose | ||||
| PE | CRG Partners IV - Parallel Fund C Cayman LP | [2019-03-29] | 600.0 M | 338.3 M |
| Filed 2019-10-11 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Revenue Decline to Disclose | ||||
| PE | CRG Partners III Cayman LP | [2016-03-29] | 89.0 M | 61.9 M |
| Filed 2016-03-18 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration One year or less · Commission $399,000 · Revenue Decline to Disclose | ||||
| PE | CRG Partners III LP | [2016-03-29] | 41.5 M | 26.5 M |
| Filed 2016-03-18 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration One year or less · Commission $124,500 · Revenue Decline to Disclose | ||||
| PE | CRG Partners III - Parallel Fund A LP | [2016-03-29] | 27.3 M | 18.9 M |
| Filed 2016-03-18 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration One year or less · Commission $409,500 · Revenue Decline to Disclose | ||||
| PE | CRG Partners III - Parallel Fund B Cayman LP | 2016-03-29 | 55.0 M | |
| View All | ||||
| AUM Breakdown | Accounts | AUM ($B) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 0 | 0.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 10 | 2.2 |
| (g) Pension and profit sharing plans | 0 | 0.0 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 0 | 0.0 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 0 | 0.0 |
| (l) Sovereign wealth funds and foreign official institutions | 0 | 0.0 |
| (m) Corporations or other businesses not listed above | 0 | 0.0 |
| (n) Other | 0 | 0.0 |
| Total | 10 | 2.2 |
| By Discretionary | ||
| Discretionary | 10 | 2.2 |
| Non-Discretionary | 0 | 0.0 |
| Total | 10 | 2.2 |
| By Non-United States Persons | ||
| Non-United States Persons | 1.7 | |
| United States Persons | 0.5 | |
| Total | 10 | 2.2 |
| Form D Directors | Role | # Filings | # Firms | 2011 - 2026 |
|---|---|---|---|---|
| Sabrina Foster | Director | 43 | 16 | |
| Omar Wright | Director | 88 | 13 | |
| Charles Tate | Executive Officer | 16 | 2 | |
| Nathan Hukill | Executive Officer, Promoter | 9 | 2 | |
| Andrei Dorenbaum | Executive Officer, Promoter | 7 | 2 | |
| Luke Duster | Executive Officer, Promoter | 6 | 2 | |
| Sebastian Arango | Promoter | 3 | 1 | |
| Adam Whitehead | Promoter | 3 | 1 | |
| Meredith Gamble | Promoter | 3 | 1 | |
| Crg Partners V Cayman GP LP | Executive Officer | 1 | 1 | |
| View All | ||||
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 3 | [0001702352] | |
| 4 | [0001702352] | |
| SC 13D | [0001702352] | |
| SC 13G | [0001702352] | |
| D | [0001747755] |
| Firm Profile (Form ADV) | |
|---|---|
| Discretionary AUM | $1.0B |
| Serves | Institutional |
| Fund Types | Private Equity |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
T2 Biosystems Inc TTOO
Common Stock
|
2024-05-09 | Conversion | 108,752 | ||
|
T2 Biosystems Inc TTOO
Series A Preferred Stock · derivative
|
2024-05-09 | Conversion | 17,160.48 | $0.00 | |
|
T2 Biosystems Inc TTOO
Series B Preferred Stock · derivative
|
2024-05-09 | Conversion | 10,875.25 | $0.00 | |
|
T2 Biosystems Inc TTOO
Common Stock
|
2024-05-09 | Conversion | 1,716,048 | ||
|
T2 Biosystems Inc TTOO
Common Stock
|
2024-05-03 | Grant | 403,608 | ||
|
T2 Biosystems Inc TTOO
Common Stock
|
2024-05-03 | Grant | 1,565,445 | ||
|
T2 Biosystems Inc TTOO
Common Stock
|
2024-05-03 | Grant | 129,629 | ||
|
T2 Biosystems Inc TTOO
Common Stock
|
2024-05-03 | Grant | 648,139 | ||
|
T2 Biosystems Inc TTOO
Common Stock
|
2024-05-03 | Grant | 2,001,514 | ||
|
T2 Biosystems Inc TTOO
Common Stock
|
2024-04-12 | Grant | 424,716 | ||
|
T2 Biosystems Inc TTOO
Series A Convertible Preferred Stock · derivative
|
2024-04-12 | Grant | 17,160.48 | $0.00 | |
|
T2 Biosystems Inc TTOO
Common Stock
|
2024-04-12 | Grant | 1,647,315 | ||
|
T2 Biosystems Inc TTOO
Common Stock
|
2024-04-12 | Grant | 682,036 | ||
|
T2 Biosystems Inc TTOO
Common Stock
|
2024-04-12 | Grant | 390,142 | ||
|
T2 Biosystems Inc TTOO
Common Stock
|
2024-04-12 | Grant | 136,409 | ||
|
T2 Biosystems Inc TTOO
Series B Preferred Stock · derivative
|
2024-02-14 | Conversion | 33,594.71 | $0.00 | |
|
T2 Biosystems Inc TTOO
Common Stock
|
2024-02-14 | Conversion | 335,947 | ||
|
T2 Biosystems Inc TTOO
Series B Preferred Stock · derivative
|
2024-02-14 | Conversion | 48,827.30 | $0.00 | |
|
T2 Biosystems Inc TTOO
Common Stock
|
2024-02-14 | Conversion | 488,273 | ||
|
T2 Biosystems Inc TTOO
Common Stock
|
2023-09-28 | Sell | 2,858,980 | $0.16 | 457,437 |
| showing 20 of 98 most recent transactions | |||||
| Comparable Firms | State | AUM |
|---|---|---|
|
Hidden Harbor Capital Management LP
✚
|
FL | 2,235.2 M |
|
EIV Capital LLC
✚
|
TX | 2,232.2 M |
|
CCMP Capital Advisors LP
✚
|
NY | 2,229.0 M |
|
Two Sigma Ventures LP
✚
|
NY | 2,226.1 M |
|
Longrange Capital LP
✚
|
CT | 2,219.6 M |
|
Further Global Capital Management LP
✚
|
NY | 2,215.6 M |
|
Kosmos Management LLC
✚
|
WA | 2,205.9 M |
|
Pacific Lake Partners LLC
✚
|
MA | 2,179.9 M |
|
CAI Manager LP
✚
|
CA | 2,177.7 M |
|
Ascend Capital Partners Manager LP
✚
|
NY | 2,176.3 M |